Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

ABSTRACT: The KMT2A-rearranged (KMT2A-r) leukemia is one of the most challenging cancers to treat in children, owing to the higher relapse rates and chemoresistance frequently observed in this patient population. At the molecular level, chromosomal translocation in the KMT2A gene leads to a deregulated epigenetic landscape resulting in the upregulation of transcription factors like HOXA9, consequently contributing to leukemogenesis. One crucial component of the oncogenic KMT2A-r complex is the involvement of positive transcription elongation factor b, which is composed of cyclin T and cyclin-dependent kinase 9 (CDK9), which leads to the dysregulation of transcriptional elongation. This study investigated the function of enitociclib, a small molecule CDK9 inhibitor in clinical developme

SUBMITTER: Sharma R 

PROVIDER: S-EPMC12447890 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature